AroCell has obtained regulatory approval for TUBEX® TF in Ethiopia

AroCell has previously announced that they have signed a distribution agreement with Sub-Saharan Biomedical P.L.C. for the sale of TUBEX® TF in Ethiopia. Over the past few months, AroCell, together with its distributor, has been working on the local regulatory process and has now obtained regulatory approval for TUBEX® TF in Ethiopia.

Attaining regulatory approval is a challenging process but provides a competitive advantage once obtained. 
 
After its launch in Africa, AroCell has focused on finding suitable distribution partners. The company has previously announced that it has signed agreements with distributors in Uganda, Ghana, and Kenya among others. These agreements involve the sale of the company's rapid test TUBEX® TF for typhoid fever.
 
"Ethiopia is a large country with 120 million inhabitants and a potentially important market for TUBEX® TF. It is gratifying that we have now accomplished the regulatory work," says Gunnar Wahlberg, Sales Manager for rapid tests at AroCell.
 

Datum 2024-01-25, kl 11:07
Källa MFN
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 15 000 unika besökare per månad. Vår discord har över 6000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!